Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Malar J ; 14: 311, 2015 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-26260055

RESUMO

BACKGROUND: Cerebral malaria (CM) is debilitating and sometimes fatal. Disease severity has been associated with poor treatment access, therapeutic complexity and drug resistance and, thus, alternative therapies are increasingly necessary. In this study, the effect of the administration of Agaricus blazei, a mushroom of Brazilian origin in a model of CM caused by Plasmodium berghei, strain ANKA, was investigated in mice. METHODS: C57BL/6 mice were pre-treated with aqueous extract or fractions of A. blazei, or chloroquine, infected with P. berghei ANKA and then followed by daily administration of A. blazei or chloroquine. Parasitaemia, body weight, survival and clinical signs of the disease were evaluated periodically. The concentration of pro-and anti-inflammatory cytokines, histopathology and in vitro analyses were performed. RESULTS: Mice treated with A. blazei aqueous extract or fraction C, that shows antioxidant activity, displayed lower parasitaemia, increased survival, reduced weight loss and protection against the development of CM. The administration of A. blazei resulted in reduced levels of TNF, IL-1ß and IL-6 production when compared to untreated P. berghei-infected mice. Agaricus blazei (aqueous extract or fraction C) treated infected mice displayed reduction of brain lesions. Although chloroquine treatment reduced parasitaemia, there was increased production of proinflammatory cytokines and damage in the CNS not observed with A. blazei treatment. Moreover, the in vitro pretreatment of infected erythrocytes followed by in vivo infection resulted in lower parasitaemia, increased survival, and little evidence of clinical signs of disease. CONCLUSIONS: This study strongly suggests that the administration of A. blazei (aqueous extract or fraction C) was effective in improving the consequences of CM in mice and may provide novel therapeutic strategies.


Assuntos
Agaricus/química , Anti-Inflamatórios/farmacologia , Antimaláricos/farmacologia , Produtos Biológicos/farmacologia , Malária Cerebral/tratamento farmacológico , Animais , Anti-Inflamatórios/química , Anti-Inflamatórios/uso terapêutico , Antimaláricos/química , Antimaláricos/uso terapêutico , Produtos Biológicos/química , Produtos Biológicos/uso terapêutico , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Citocinas/sangue , Feminino , Malária Cerebral/fisiopatologia , Malária Cerebral/prevenção & controle , Camundongos , Camundongos Endogâmicos C57BL
2.
Eur Neuropsychopharmacol ; 24(7): 1139-43, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24731723

RESUMO

Telomeres are DNA-protein complexes that cap linear DNA strands, protecting DNA from damage. Recently, shorten telomeres length has been reported in bipolar disorder (BD) and depression. The enzyme telomerase regulates telomeres׳ length, which has been associated with cellular viability; however it is not clear how telomerase may be involved in the pathophysiology and therapeutics of BD. In the present study, leukocyte telomerase activity was assessed in 28 medication-free BD depressed individuals (DSM-IV-TR criteria) at baseline and after 6 weeks of lithium therapy (n=21) also matching with 23 healthy controls. There was no difference between telomerase activity in subjects with BD depression (before or after lithium) and controls. Improvement of depressive symptoms was negatively associated with telomerase activity after 6 weeks of lithium therapy. This is the first study describing telomerase activity in BD research. Overall, telomerase activity seems not directly involved in the pathophysiology of short-term BD. Lithium׳s antidepressant effects may involve regulation at telomerase activity. Further studies with larger samples and long-term illness are also warranted.


Assuntos
Antidepressivos/uso terapêutico , Transtorno Bipolar/enzimologia , Leucócitos/enzimologia , Lítio/uso terapêutico , Telomerase/metabolismo , Adulto , Transtorno Bipolar/sangue , Transtorno Bipolar/tratamento farmacológico , Feminino , Humanos , Masculino , Resultado do Tratamento , Adulto Jovem
3.
Proc Natl Acad Sci U S A ; 108(49): 19695-700, 2011 Dec 06.
Artigo em Inglês | MEDLINE | ID: mdl-22114198

RESUMO

One of the main challenges in cancer research is the development of vaccines that induce effective and long-lived protective immunity against tumors. Significant progress has been made in identifying members of the cancer testis antigen family as potential vaccine candidates. However, an ideal form for antigen delivery that induces robust and sustainable antigen-specific T-cell responses, and in particular of CD8(+) T lymphocytes, remains to be developed. Here we report the use of a recombinant nonpathogenic clone of Trypanosoma cruzi as a vaccine vector to induce vigorous and long-term T cell-mediated immunity. The rationale for using the highly attenuated T. cruzi clone was (i) the ability of the parasite to persist in host tissues and therefore to induce a long-term antigen-specific immune response; (ii) the existence of intrinsic parasite agonists for Toll-like receptors and consequent induction of highly polarized T helper cell type 1 responses; and (iii) the parasite replication in the host cell cytoplasm, leading to direct antigen presentation through the endogenous pathway and consequent induction of antigen-specific CD8(+) T cells. Importantly, we found that parasites expressing a cancer testis antigen (NY-ESO-1) were able to elicit human antigen-specific T-cell responses in vitro and solid protection against melanoma in a mouse model. Furthermore, in a therapeutic protocol, the parasites expressing NY-ESO-1 delayed the rate of tumor development in mice. We conclude that the T. cruzi vector is highly efficient in inducing T cell-mediated immunity and protection against cancer cells. More broadly, this strategy could be used to elicit a long-term T cell-mediated immunity and used for prophylaxis or therapy of chronic infectious diseases.


Assuntos
Antígenos de Neoplasias/imunologia , Vacinas Anticâncer/imunologia , Proteínas de Membrana/imunologia , Trypanosoma cruzi/imunologia , Animais , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/metabolismo , Western Blotting , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/parasitologia , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/parasitologia , Vacinas Anticâncer/administração & dosagem , Linhagem Celular Tumoral , Células Cultivadas , Doença de Chagas/imunologia , Doença de Chagas/parasitologia , Doença de Chagas/prevenção & controle , Ensaio de Imunoadsorção Enzimática , Vetores Genéticos/administração & dosagem , Vetores Genéticos/imunologia , Humanos , Imunização/métodos , Masculino , Proteínas de Membrana/genética , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Neoplasias Experimentais/imunologia , Neoplasias Experimentais/patologia , Neoplasias Experimentais/prevenção & controle , Transfecção/métodos , Trypanosoma cruzi/genética , Trypanosoma cruzi/metabolismo
4.
J Microbiol Methods ; 69(3): 518-22, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17466399

RESUMO

Aiming to replace the radioisotopic assay, the widely used procedure for vitro antimalarial drug screening, we set up a protocol using a Plasmodium falciparum strain transformed with the green fluorescent protein (PfGFP), which can be quickly and specifically quantified by flow cytometry. On the basis of a side-by-side comparison, this PfGFP-based method showed results similar to those obtained with the standard radioisotopic method.


Assuntos
Antimaláricos/farmacologia , Citometria de Fluxo/métodos , Proteínas de Fluorescência Verde/genética , Plasmodium falciparum/efeitos dos fármacos , Transformação Genética , Animais , Avaliação Pré-Clínica de Medicamentos , Eritrócitos/parasitologia , Proteínas de Fluorescência Verde/metabolismo , Humanos , Hipoxantina/metabolismo , Testes de Sensibilidade Parasitária/métodos , Plasmodium falciparum/genética , Plasmodium falciparum/crescimento & desenvolvimento , Plasmodium falciparum/metabolismo , Transfecção , Trítio/metabolismo
5.
Exp Parasitol ; 116(4): 346-53, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17376436

RESUMO

While seeking strategies for interfering with Plasmodium development in vertebrate/invertebrate hosts, we tested the activity of gomesin, an antimicrobial peptide isolated from the hemocytes of the spider Acanthoscurria gomesiana. Gomesin was tested against asexual, sexual and pre-sporogonic forms of Plasmodium falciparum and Plasmodium berghei parasites. The peptide inhibited the in vitro growth of intraerythrocytic forms of P. falciparum. When gomesin was added to in vitro culture of P. berghei mature gametocytes, it significantly inhibited the exflagellation of male gametes and the formation of ookinetes. In vivo, the peptide reduced the number of oocysts of both Plasmodium species in Anopheles stephensi mosquitoes, and did not appear to affect the mosquitoes. These properties make gomesin an excellent candidate as a transmission blocking agent for the genetic engineering of mosquitoes.


Assuntos
Antimaláricos/farmacologia , Peptídeos Catiônicos Antimicrobianos/farmacologia , Estágios do Ciclo de Vida/efeitos dos fármacos , Plasmodium berghei/efeitos dos fármacos , Plasmodium falciparum/efeitos dos fármacos , Animais , Anopheles/efeitos dos fármacos , Anopheles/parasitologia , Artemisininas/farmacologia , Artesunato , Eritrócitos/parasitologia , Feminino , Células Germinativas/efeitos dos fármacos , Células Germinativas/crescimento & desenvolvimento , Humanos , Masculino , Camundongos , Oocistos/efeitos dos fármacos , Plasmodium berghei/crescimento & desenvolvimento , Plasmodium falciparum/crescimento & desenvolvimento , Sesquiterpenos/farmacologia
6.
Mol Immunol ; 40(16): 1149-56, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15104120

RESUMO

Low molecular weight hemorrhagins were purified from crude Bothrops atrox snake venom by gel filtration followed by ionic strength chromatography. The protein fractions obtained, designated HI-1 to HI-8, contained proteins with molecular masses lower than 30 kDa. HI-5, the most representative among of these fractions, exhibited, in vitro, proteolytic and C inactivating properties, as analyzed by proteolysis of a protein substrate, and C system consumptive activities as assayed by reduction of the hemolytic C activity in normal human serum and by cleavage of partially purified component C3. HI-5 hemorrhagin injected i.m. into C-sufficient BALB/c mice induced a local inflammation characterized by edema, accumulation of polymorphonuclear leucocytes (PMN) and hemorrhage. In contrast, when injected into BALB/c mice previously C-depleted, the number of PMN per tissue section, but not hemorrhage, was significantly reduced (129.668 +/- 31.341 cells per microscopic field) as compared with the control C-sufficient mice (812.168 +/- 111.194 cells per microscopic field). The observations were confirmed by using C5-deficient mice instead of C-depleted mice. The average number of PMN per tissue section in C5-defficient A/J mice was 72.666 +/- 19.416 cells per microscopic field. These data indicate that the C system is involved in PMN accumulation, but not in the hemorrhage, at the local induced lesions by low molecular mass B. atrox hemorrhagins. HI-5 apparently is not contaminated with other direct or indirect inflammation mediators, PMN accumulation and hemorrhage, however, an independent phenomenon, could be mediated by the same hemorrhagin proteinase domain.


Assuntos
Bothrops , Proteínas do Sistema Complemento/fisiologia , Venenos de Crotalídeos/enzimologia , Inflamação/induzido quimicamente , Metaloendopeptidases/toxicidade , Neutrófilos/metabolismo , Animais , Complemento C5/imunologia , Ensaio de Atividade Hemolítica de Complemento , Proteínas do Sistema Complemento/deficiência , Venenos de Crotalídeos/toxicidade , Edema/induzido quimicamente , Hemorragia/induzido quimicamente , Humanos , Inflamação/patologia , Injeções Intramusculares , Metaloendopeptidases/isolamento & purificação , Camundongos , Camundongos Endogâmicos A , Camundongos Endogâmicos BALB C , Peso Molecular , Músculo Esquelético/patologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/patologia , Soro/metabolismo , Especificidade da Espécie
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...